San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...

Researchers have found in a new study that the novel Lesifter device shows encouraging early efficacy and a favorable safety profile in reducing stroke risk among patients with atrial ...

HOLLYWOOD, FL—Several large-bore closure devices seem poised to soon enter the US interventionalist’s toolbox, with “explosive growth” expected in their use given the rise in transcatheter aortic ...

WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient was enrolled in the ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

In the PROTECT AF trial, patients randomized to left atrial appendage closure initially continued taking warfarin and aspirin to promote device endothelialization. At 45 days after the procedure, 86.8 ...

Percutaneously implanted devices designed to seal off the left atrial appendage (LAA) have been around for some time, but a recent study of surgical closure of the appendage might have a beneficial ...

Percutaneous closure of patent foramen ovale (PFO) is a widely used procedure, but the long-term safety and efficacy of the technique have not been investigated. This prospective, observational, ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...